Sign In
Buy CPRX
$31.28
+0.0100 (+0.0320%)
At Close: Jun 03, 2026
Catalyst Pharmaceuticals: Clear Path Forward For Growth In 2 FDA-Approved Drugs
11:39am, Thursday, 19'th Feb 2026
Catalyst Pharmaceuticals management asserts a $1B+ LEMS market opportunity, estimating 3,600–5,400 addressable patients, with growth driven by improved diagnosis and market penetration. Recent prese
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock
10:41am, Thursday, 19'th Feb 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Analysts Estimate Catalyst Pharmaceutical (CPRX) to Report a Decline in Earnings: What to Look Out for
11:05am, Wednesday, 18'th Feb 2026
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
08:03am, Wednesday, 11'th Feb 2026
The Company will Host a Conference Call and Webcast on Thursday, February 26, 2026, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, February 26, 2026, at 8:30 AM ET
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
10:41am, Tuesday, 03'rd Feb 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
10:50am, Wednesday, 28'th Jan 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
2 Under-the-Radar Biotech Stocks Set to Boom in 2026
02:00pm, Saturday, 24'th Jan 2026
Halozyme Therapeutics and Catalyst Pharmaceuticals are notching double-digit increases in revenue and EPS. With little debt on their balance sheets, these companies can consider acquisitions.
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock
10:40am, Thursday, 15'th Jan 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
09:25pm, Monday, 12'th Jan 2026
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CPRX or DSNKY: Which Is the Better Value Stock Right Now?
12:40pm, Friday, 09'th Jan 2026
Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Is Catalyst Pharmaceuticals (CPRX) Stock Undervalued Right Now?
10:40am, Thursday, 08'th Jan 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies
08:03am, Thursday, 08'th Jan 2026
CORAL GABLES, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)
08:03am, Monday, 05'th Jan 2026
CORAL GABLES, Fla. , Jan. 05, 2026 (GLOBE NEWSWIRE) -- The University of Notre Dame and Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical co
Catalyst Pharmaceuticals Executive Cashes Out 10,983 Shares -- What's Behind the Move?
11:06am, Wednesday, 31'st Dec 2025
Jeffrey Del Carmen, Chief Commercial Officer of Catalyst Pharmaceuticals (CPRX +0.21%), exercised and immediately sold 10,983 shares of common stock on November 26, 2025, for a total value of approxim
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
10:41am, Tuesday, 30'th Dec 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
